Preclinical Investigation Shows Ground-Breaking Results on Human Infections

Preclinical Investigation Shows Ground-Breaking Results on Human Infections PR Newswire RHEINBREITBACH, Germany, November 14, 2012 RHEINBREITBACH, Germany, November 14, 2012 /PRNewswire/ -- Synthetic human-milk-oligosaccharides reduce the risk of infections caused by hazardous pathogens Human-milk-oligosaccharides, an important component of human mother's milk, play a fundamental role in the protection of infants against viral and bacterial infection. Preclinical studies carried out by Jennewein Biotechnologie GmbH have now shown for the first time that synthetically produced functional sugars protect humans from infectious diseases. The investigations were conducted in collaboration with the University Children's Hospital Mannheim of Heidelberg University (GER). In collaboration with the University Children's Hospital Mannheim of Heidelberg University, Jennewein Biotechnologie GmbH carried out extensive preclinical research to demonstrate for the first time that synthetic human-milk- oligosaccharides achieve the same protective effects as natural sugars in human breast milk. The study focused on the human-milk-oligosaccharides 2'-Fucosyllactose and 3-Fucosyllactose, which are present in human breast milk at levels of up to 3.5 grams per liter and are by far the most abundant human-milk-oligosaccharides. The researchers at Mannheim (GER) tested the sugars on human cells using various pathogens. The results demonstrate a clear protective effect, i.e.